Tram, Thank and you, afternoon, everyone. good
me business, commercial is company and and injector specialty on business diversified leading ENHANZE a with drug delivery robust platform technology Let three. include business, a our slide a royalty auto our portfolio. which Halozyme begin
throughout our plan year and XXXX we pleased to report million, that up for year. the the year-over-year. result us XXXX well growth that will record we revenue total This first expect quarter increase I'm quarter-over-quarter of revenue XX% for executed in achieving a $XXX of performance another revenue sets strong
leadership more injectors. our subcutaneous delivery now auto the established delivery the Halozyme momentum rapid [indiscernible], slide of drug delighted our drug I'm and business. differentiated recently, with ENHANZE, Turning our has of with to four. in
development are with in partners their to progress long-term durable commercialization strong result Our growth. activities making that and strong and expected are
and approval OCREVUS launch and Two with fixed-dose approved to the with continuing and An also subcu for bring Vivo blockbuster potential XXXX potential Phase between drugs XXXX. Phase XXXX. X from efgartigimod Drivers atezolizumab continuing subcu subcu generating year this relatlimab/nivolumab will launch launch subcu product amivantamab additional testing, products, the products seven of and the combination products. our to that potential clinical development subcu growth before royalties and include of this five by royalty generation final phase potential the a additional two X subcu
to three a And year also new adding our for it high-volume robust ENHANZE our is by goal injector auto plus our to volume agreements agreement. add this pipeline injector ENHANZE, auto already and small
are so Subcu five, our with burden slide to when to ability me partners for excited moment and and subcutaneous delivery product on a an treatment many decreases from subcutaneous let IV. Turning drug about are demonstrated products, why has times co-formulated patients. focused spend the delivery partner treatment so with on differentiate ENHANZE, ENHANZE.
a results centers patient of be, and advantages This in of regions infusion saw in healthcare growing turn also in use consideration case world. costly These include stating less the advantages system. This translate into rate patient less related hospitals use experience lower in preference a considerable can an also as we the of for with more time, to surveys. strong of subcu practitioner and of in subcutaneous, improved a may DARZALEX reactions. infusion the There healthcare all
launch with The and six, that moment. the I'll into and between Wave and launch those X launched to more potential slide detail are of terms products go XXXX. a X for XXXX XXXX to now this with products. overview We between waves and on Waves the potential X And the XXXX. X, Moving already ENHANZE those Wave in X I'll described in product, the X an of X our provide pipeline. Waves have
an disorders. X by these let available may management I so, product. community is indication flexible expanded of impacted HYQVIA Wave a for for HYQVIA immunodeficiency event to prefer in primary children. approval our now an the for immunodeficiency options exciting before one of in primary treat broader who to FDA highlight me do Takeda But received treatment
key extensive impact for royalty This our development XXXX our the our growth and approximately beyond expectations potential patents. billion for launches driver supports value having co-formulation the new and pipeline reach $X driven is with for partners revenues And growth projected in that. to projected by of
in royalty throughout now Let XX% XX% in XXXX, of overview strong $XX.X project We our million XXXX. to seven and $XXX year-over-year me increased to $XXX royalty Quarterly revenues. for over to growth quarter-on-quarter XXXX. an to growth we million move million royalty project revenue XX% slide revenue
products, drug partner revenue are an using DARZALEX Wave contributing are growth growth to markets drivers. the Phesgo global and with XXX approximately ENHANZE date products, royalty commercialized Five delivery subcu and X key technology to
and reimbursement. While no the virtually to seen revenues driven physicians regarding included Tecentriq revenue generic EpiPen. approval time auto subcu and is we confident States efgartigimod small in Teva's royalty in from the remains the XXXX This project timing standard by United of Also royalty and XXXX, we've for from takes these stable due subcu products launch our be largely it business. revenue to volume our in in injector
market story, XXXX Moving details on This an the $X.X gains Janssen's in the to to the DARZALEX share in of growth amazing basis strong I'll to slide continue by quarter with and J&J more in DARZALEX approximately formulation growing all subcutaneous driven first billion. the DARZALEX. eight, expects setting. approximately first-line now XX% regions, grow DARZALEX to continues of continued adoption operational ENHANZE. was FASPRO, on provide growth its year-over-year increase
XX% the metric continue as myeloma $XX.X driver The meaningfully to subcutaneous as States. DARZALEX exceeding the a physicians overall United revenues DARZALEX is now is annual until royalty was in of brand at and share will last the XXXX United subcu. Analysts of XXXX. established the outside States, using the by contribute a for of key choice XXXX. performance in this patients, are track in DARZALEX and key driven billion Janssen, by we DARZALEX now growth with our least reach is now subcu globally projecting reported will sales XX%
Herceptin Turning HER-X now is with allows to subcutaneous Phesgo Perjeta cancer. eight to treatment positive for five nine. a breast of metastatic minutes lengthier for and a injection treatment IV combination compared slide and schedule. patients Roche's for subcutaneous This on Phesgo early with single a
XX% that preferred of reported intravenous administration recently Phesgo subcutaneous and Roche patients Perjeta Herceptin. over of the formulation
CHFXXX Over of Phesgo XXXX, quarter first the year-over-year. Roche approximately sales of reported of an XX% increase million,
United and for the share for their recognizes overall. subcutaneous of the pioneer, countries, the initial the Roche, is with clearly focus exceeding outside is States Phesgo system and In XX% Germany a US the approaching launch benefits healthcare with XX%. XX%, patients, now on patients drug delivery XX
expect from path We Phase from beyond. growth for in and self-administration with on-body also in Phesgo of is project XXXX program this Roche the injector data continued half and developing an patient second of year. X pivotal a the Phesgo
enabled these likelihood subcutaneous ocrelizumab, formulation. slide the XXXX our all products. which which Next products are shown royalty on for set Wave atezolizumab, products are and with Wave efgartigimod, nivolumab versions the XX. This represent of IV indication These confidence are proven of X and and XXXX. one Halozyme X products, revenue of projected next for us subcutaneous launches approval The between at opportunities as up gives ENHANZE of least are potential an
Argenx's billion occurring for total approximately subcu sales $XX myasthenia the efgartigimod XXXX. date through key has $X total application this also including I project revenue Agency. with events its year analysts advancements will IV gravis in approximately XX, billion subcutaneous exciting submitted XXXX. in and of annual an FDA Analysts Medical where a and summarize potential Argenx generalized authorization the June this of efgartigimod PDUFA portfolio marketing European has to predict XXXX.
the in of well reported year. The the growth first to quarter formulation with this of launch in certainly million is and IV progressing XXXX $XXX $XXX quarter-over-quarter XX% of a million
has projected are to of We efgartigimod the our launches and Wave XXXX. mid-year commercial be US the partner excited first subcutaneous launch that with approval X potential
argenx's on may On trajectory the importance quarterly achieve subcutaneous early line this. help approval management their of commented traction in the continued patients gaining that the call, for and recent
currently autoimmune will six is of that with argenx's treatment today for in pipeline efgartigimod multiple I indications. flagship developed As these of indications indications. only note subcutaneous product subcutaneous disease being are development indications the four
readout chronic polyneuropathy demyelinating inflammatory a and projected data for eye in in idiopathic year. Two data indications, thrombocytopenia data thyroid plans fourth announced readouts in to for including plan study additional are has for in the argenx two And multiple includes quarter now of this XXXX This X Argenx project purpura pemphigus. Phase expand later July autoimmune of XXXX. new disease add XXXX. conditions, and serious additional additional
for IV patients atezolizumab now to XX compared seven a time Roche accepted XX, beginning to physicians XXXX. the an minutes to move PDUFA to with Roche. with has FDA atezolizumab subcutaneous I'll treatment. of potential for BLA announced with September was Subcutaneous ENHANZE convenience subcutaneous to year, greater their offer XX the the of At approximately date and for the minutes administration
for represents US million, this Tecentriq constrained where higher an a demand by of the reported resources are of first system believes XXXX, IV as CHFXXX as increase year-over-year, the revenues quarter the Europe. payers. for Roche of In well XX% advancement driven in significant and healthcare Roche patients, in
XX% OCREVUS, first a XXX,XXX share and increase Wave which EUX, to reported X on rate retention higher and billion one OCREVUS billion. the than of than therapies CHFX.X patients multiple the with annualizes of US at globally, also quarter remains terms OCREVUS for opportunity. number treated revenues an year-over-year Roche is $X sclerosis. treatment share in With of total represents in over more new for XXXX other brand third and both
treatment where significantly is hours IV and IV with The to currently to OCREVUS the time the goal subcutaneous to hours. compared X shorten the is observation X.X
the expected is whom and and XX to opportunity each the second data an will subcutaneous first ocrelizumab the administration time the excited for lower just to provide subcutaneous this for target ENHANZE one dose observation access dose. and to of trial hour to intravenous year, for viable. the that X total could for and dosing patients subcutaneous expand Roche for later the administration With delivery minutes provide Phase readout market subsequent observation not data is with and
utilizing product, sales of subcutaneous ENHANZE reported IV OPDIVO and billion to our fourth progressing year-over-year [indiscernible] nivolumab of Moving the drug $X.X XX% their of patients first quarter FX. or renal registration XX% in with they forward X subcutaneous believes increase X with carcinoma. cell of now of Wave that XXXX, in are Phase delivery BMS BMS study an excluding nivolumab.
of is by XXXX, date. to potential near-term billion Our driving approximately Wave Phase opportunity Wave our than which X represented approvals opportunity and terms in X Halozyme, is our royalty which subcutaneous The for analyst ocrelizumab. revenue products for year X $XX of revenue the de-risked significantly readout growth this substantial opportunity for in represent product are new products driven two higher projections the royalty total sales strong here
our Wave pipeline with review I'll XX, X partner Moving product Slide to development ENHANZE.
longer-term Phase two XX in timeframe. which X. by Our are trajectory products supported testing comprised Wave is completed Phase potential partner these X Wave further X of have through ongoing are X products, in XXXX with growth or clinical XXXX of launches the in Phase X and remaining eight the is
our and streams. approval continue beyond, of the BMS' Janssen's products are relatlimab and In of to to ENHANZE. products development goal advanced subcutaneous fixed-dose amivantamab and royalty to revenue with launch most development combination advance plus adding and XXXX nivolumab regulatory is expand The in two through products to number new multiple
in Phase with are approved and IV not plus exposure initiated amivantamab cancer. previously patients metastatic nivolumab showing is study clinical study X of in testing fixed-dose demonstrating untreated their RELATIVITY-XXX, drug combination combination recently relatlimab ENHANZE being with cell ENHANZE subcu initiated in to treatment in done with with And administration Phase and with in melanoma. IV goal lung or already unresectable advanced Janssen that of lazertinib study, growth also X of of X as BMS non-small versions. XXXX same are EGFR mutated the level the metastatic theater the plus or as Both patients Phase with strong this
X further thereby goal NXLS, patients subcutaneous interval Wave drugs extend our as broadly are antibody development treatment and dosing HIV. subcutaneous rilpivirine, X oral IM in with has innovation Phase burden approved Janssen's for pipeline the to delivery stage include freeing and the ViiV's the HIV. Phase neutralizing with with ViiV program and their development development is of disease. ENHANZE. notable X stated already ViiV is a for in in cabotegravir both Other delivery as with further also focus on
partnership delivery. new interest I'll and opportunities. drug now all-time at by new to discussions remain with that move I'm injectors. high growth subcutaneous the of We our excited funnel engaged discussions our ENHANZE for is high in highly auto driven an
confident auto are new that to While one always deal. will timing predict, ENHANZE we deals, volume the new achieve auto one plus injector for small one high injector deal difficult goals volume for ENHANZE is XXXX and we our new
We rapid about more are up for enabled ENHANZE. experiencing of to learning mL, injector strong delivery interest which high-volume our in by is auto XX
a patient areas will approach for friendly, drugs can opportunity and volume, truly the high utilized across This subcutaneous be that of offer biologics. molecule differentiated disease both for small delivery spectrum
We and signing to studies initiate human towards to mid-year. prototype expect have the complete an forward this for We collaborate working feasibility and clinical to are agreement a on a by new with current a or nicely partner goal. tracking testing ready custom development look and
delivered are auto and weekly, I'll includes is virtually which now to shown treatment, subcutaneous is by slide replacement patient turn a TLANDO painless XYOSTED testosterone and injector. on XYOSTED our XX. commercial portfolio which
from approach most intramuscular date. the Our patients growth injections, to on remains converting treatment strategy common focused
quarter, average weekly month. prescription XYOSTED. through the the physician not patients every for strong on we resetting navigated barrier deductible card affordability starting growth achieving saw the We was high of for first of or a XYOSTED helping In staying commercial performance successfully program, our quarter high new assure copay demand
lag slightly demand XPL our as in quarter of a result wholesalers to channel. distribution the change the Sales in
Our revenue a rate achieve from in goal following acquisition. approximately increase XYOSTED remains to XXXX, run $XXX million the in the XX% representing
until on access XXXX. pharmacy TLANDO appropriate TLANDO, we yet rate. To-date, gaining also an revenues managers And still benefit on established, projecting for is in reached testosterone are agreement we're our oral no rebate we focused not have for treatment. with access And
Before the and is me our on over growth our Nicole, let call I strategic capital shown XX. allocation commitment reiterate priorities, hand to which to slide
for technology buyback shareholders to share stakeholders. We're to revenue capital strategically of committed value plan. and our to continuing all are We injector maximizing while growth our auto to durability investing ENHANZE our and long-term in create with return our
first quarter this or with for was million share share program, million de-risked in the taking M&A or opportunities, see and XXXX significant $XXX revenue platforms of we the We've growth December completed buyback buyback completed evaluating the $XXX includes companies XXXX. We're by in million where of actively also three-year Board platforms and Directors additional or of technologies the opportunity which approved durability. assets of $XXX
I'll now over the first Nicole of financial results quarter call for turn our discuss to the to Nicole? XXXX.
